Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:
”Low-dose colchicine (0.5 mg/day) has emerged as an effective anti-inflammatory strategy for secondary prevention in atherosclerotic cardiovascular disease.
By inhibiting microtubule assembly, colchicine suppresses activation of the NLRP3 inflammasome, leading to reduced interleukin-1β and interleukin-6 signaling, key drivers of plaque inflammation and instability.
Clinical trial data demonstrate that colchicine significantly stabilizes atherosclerotic plaques, attenuates neutrophil activation, and reduces thrombogenic potential.
A pooled analysis of randomized trials shows a 25% relative reduction in major adverse cardiovascular events (HR ~0.75), with consistent reductions in myocardial infarction (≈23%), ischemic stroke (≈22%), and cardiovascular mortality (≈34%).
These benefits occur without an increase in non-cardiovascular mortality and with good tolerability in most patients.
Taken together, these findings position colchicine as a third pillar of secondary prevention, complementing lipid-lowering and antithrombotic therapies by targeting residual inflammatory risk in patients with established atherosclerosis.”
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 17:11Owen McCarty: Understanding Prekallikrein and Its Role in Inflammation and Thrombosis
-
Oct 18, 2026, 17:04Emna Gouider Belhadjali: Don’t Miss GPAS 2026 on Bleeding Disorders
-
Oct 18, 2026, 16:53Mehran Ghasemzadeh: Microparticle-Associated Mitochondrial DNA in Stored Platelet Products
-
Oct 18, 2026, 16:38Edward Lee Carter: A 15-Minute Blood Test for Brain Hemorrhage?
-
Oct 18, 2026, 16:29Patrick Taylor: Oral vs Transdermal Estrogen and Cardiovascular Risk in Menopausal Women
-
Oct 18, 2026, 16:19Artangela Henry: A Meaningful Week at the SCDAA National Convention
-
Oct 18, 2026, 16:04Emília Araújo։ New Insights Into the Genetics of Hemophilia B Leyden
-
Oct 18, 2026, 15:43André Marcel Harris: Award-Winning Research on Texas Sickle Cell Data Collection
-
Oct 18, 2026, 15:21Eleonora Gambineri: First Results of the IEI-Haem Consortium at ESID 2026